California Supreme Court rules drugmakers have no 'duty to innovate' safer products in Gilead Sciences case

On August 3, 2026, the California Supreme Court ruled 6-1 in favor of Gilead Sciences, dismissing negligence claims from 24,000 HIV patients. The court rejected a 'duty to innovate,' finding that drugmakers are not liable for halting development of safer alternatives if their existing drugs are safe. Patients had accused Gilead of delaying a safer drug, TAF, to maximize profits from its predecessor, TDF. While the majority warned of burdens on innovation, dissenting Justice Kelli Evans called Gilead's conduct morally blameworthy.

Duty to innovate rejection

• ▪The California Supreme Court's decision on August 3, 2026, reversed a February 2024 ruling by a mid-level state appeals court that had established a "duty to innovate."
• ▪The California Supreme Court ruled on August 3, 2026, that drug manufacturers do not owe a duty to patients to develop safer alternative drugs if their existing drugs are considered safe.

Gilead HIV drug litigation

• ▪HIV drugs accounted for 70% of Gilead Sciences' $29.4 billion in total revenue in 2025.
• ▪An estimated 24,000 HIV patients brought negligence claims against Gilead Sciences over its decision to halt development of an alternative drug with fewer side effects.

TDF versus TAF development

• ▪Gilead Sciences began testing tenofovir alafenamide fumarate (TAF) as a safer alternative to TDF but halted development in 2004, concluding the safety and effectiveness differences did not justify the expense.
• ▪Gilead Sciences' HIV drugs made with tenofovir disoproxil fumarate (TDF) received U.S. approval in 2001 despite potential side effects including kidney dysfunction and bone problems.
• ▪HIV patients accused Gilead Sciences of delaying TAF's commercialization for nearly a decade to maximize profits and align with the 2017 expiration of TDF's patent exclusivity.

Pharmaceutical liability standards

• ▪Dozens of trade groups and pharmaceutical companies, including Bayer, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Pfizer, supported Gilead Sciences' appeal.
• ▪Critics argued that imposing a duty to innovate would make drug development too costly, cap profits from successful drugs, and deprive patients of working treatments.

Patient negligence claims dismissal

• ▪In a 6-1 decision on August 3, 2026, the California Supreme Court ordered the dismissal of negligence claims against Gilead Sciences.
• ▪Justice Joshua Groban wrote for the majority that imposing sweeping liability for nondefective drugs would create substantial burdens and risk adverse consequences for innovation, public health, and patient safety.

Justice Evans dissenting opinion

• ▪Justice Kelli Evans dissented from the California Supreme Court's decision, characterizing Gilead Sciences' conduct as "morally blameworthy."
• ▪Justice Kelli Evans urged the California legislature to consider eliminating drug industry immunity from negligence claims.